TWA
YMAB

TCI Wealth Advisors’s Y-mAbs Therapeutics YMAB Stock Holding History

TCI Wealth Advisors’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-249
Closed -$4K – 2491
2021
Q4 		$4K Buy
249
+160
+180% +$3.42K ﹤0.01% 1927
2021
Q3 		$3K Buy
89
+27
+44% +$851 ﹤0.01% 2040
2021
Q2 		$2K Buy
+62
New +$1.99K ﹤0.01% 2118

Other funds holding YMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

TCI Wealth Advisors's YMAB Position: Q1 2022 in Review

TCI Wealth Advisors sold out of Y-mAbs Therapeutics (YMAB) in Q1 2022, closing a stake of 249 shares — an estimated $4K sold.

TCI Wealth Advisors first reported a position in YMAB in Q2 2021 and held it in 3 quarters. The position peaked at $4K in Q4 2021. 88 funds tracked by Wall St. Rank hold YMAB as of Q1 2022.

  • TCI Wealth Advisors reported no remaining Y-mAbs Therapeutics position as of Q1 2022 after selling out during the quarter.
  • TCI Wealth Advisors sold 249 Y-mAbs Therapeutics shares in Q1 2022, an estimated $4K.
  • TCI Wealth Advisors first reported a position in Y-mAbs Therapeutics in Q2 2021 and held it in 3 quarters.
  • TCI Wealth Advisors's Y-mAbs Therapeutics position peaked at $4K in Q4 2021.
  • 88 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2022.

Based on TCI Wealth Advisors's 13F filing for Q1 2022, filed 29 Apr 2022.